在败血症狗的Dexmedetomidine静脉输液的影响:初步研究
Chiara Di Franco1, Søren Boysen2, Iacopo Vannozzi1
1Department of Veterinary Sciences, University of Pisa, 56124 Pisa, Italy.
Animals : an open access journal from MDPI
|March 28, 2024
概括
在接受手术的败血症狗中,持续输注德克斯梅德托米丁 (DEX) 减少了对血管压缩剂的需求. 这种治疗似乎也降低了这些患者的28天死亡率.
科学领域:
- 兽医麻醉 兽医麻醉是什么
- 关键护理医学 关键护理医学
- 败血症研究 败血症研究
背景情况:
- 败血症在兽医手术中带来了重大挑战,往往需要血管压缩剂支持.
- 在手术过程中对败血症患者的血液动力学管理对于结果至关重要.
研究的目的:
- 调查德克斯梅德托米丁连续速率输液 (CRI) 在手术期间减少败血症狗血管压缩剂需求的有效性.
- 评估德克斯梅德托米丁对生命指标,器官衰竭得分和生存率的影响.
主要方法:
- 接受手术的败血症狗被随机分配给接收德克斯梅托米丁 (1毫克/公斤/小时CRI) 或盐水 (NaCl) 控制输液.
- 血液动力学参数,序列器官衰竭评估 (SOFA) 评分,血管压缩剂剂量和28天死亡率都被仔细记录下来.
- 标准化麻醉方案和液体复苏策略被采用,血管压缩剂的使用遵循严格的标准.
主要成果:
- 与对照组相比,德克斯梅德托米丁组需要显著降低诺尔上腺素剂量.
- 在 dexmedetomidine 组中,手术期间的低血压得到了更有效的管理.
- 在接受德克斯梅德托米丁的狗中观察到28天死亡率的统计显著减少.
结论:
- 以1mcg/kg/h的连续速率输注德克斯梅德托米丁有效降低了败血症狗的手术内血管压缩剂需求.
- 德克斯梅德托米丁的使用可能是一个有价值的治疗策略,用于改善接受手术的败血症狗的生存率.
关键词:
在CRI中,CRI是最重要的.这是一个SOFAFA.德克斯梅德米丁 (Dexmedetomidine) 是一种制剂.狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗狗qSOFAFA 的时间这是一种血症.更多相关视频
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
2.8K
07:15In vivo Macrophage Imaging Using MR Targeted Contrast Agent for Longitudinal Evaluation of Septic Arthritis
Published on: October 20, 2013
9.3K
相关概念视频
01:24Parenteral Anesthetics: Overview
120
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
120
01:19Depolarizing Blockers: Pharmocokinetics
325
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
325